Journal
PET CLINICS
Volume 7, Issue 1, Pages 119-+Publisher
ELSEVIER INC
DOI: 10.1016/j.cpet.2011.12.007
Keywords
Phosphorus-31 magnetic resonances spectroscopy; Hydrogen-1 magnetic resonance spectroscopy; Lactate; Choline
Funding
- National Institute of Health [CA101700, CA41078, CA118559]
- National Cancer Institute Small Animal Resource grant
- [5P30CA016520-34]
- NATIONAL CANCER INSTITUTE [P30CA016520, P01CA041078, R01CA101700, U24CA083105, R01CA096856, R01CA118559, R01CA089194, R21CA152858] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Pretreatment P-31 magnetic resonance (MRS) when applied to a cadre of 41 non-Hodgkin's lymphoma (NHL) regardless of disease type or stage and regardless of therapeutic regimen, was able to predict about two thirds of the patients that exhibited a complete response (CR; sensitivity 0.92, specificity 0.79). However, when the study was restricted to 27 NHL patients with the most common form of NHL, diffuse large B-cell lymphoma, all of whom were treated with RCHOP (rituximab plus CHOP chemotherapy) or RCHOP-like therapy, was able to predict CR and non-CR with a sensitivity of 1.0 and specificity of 0.90 by Fisher analysis). Patients predicted not to exhibit a CR could be directed to more vigorous therapeutic regimens followed by bone marrow transplantation or to experimental new therapeutic agents. This article highlights a general strategy for non-invasively monitoring response to inhibitors of specific signal transduction pathways by monitoring the corresponding metabolic pathway that is modified by signal transduction inhibition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available